Qili Weilin (奇力威林)奇力威林
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 海口奇力制药股份有限公司Chinese legal name: 海口奇力制药股份有限公司
主要成分Active Ingredients
- 利巴韦林Liba Weilin
药物知识说明
利巴韦林是一种在国家药监局注册认定的药品。该药品含有利巴韦林-e1136c4c等成分。
该药品关联的活性成分包括：利巴韦林Liba Weilin。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：海口奇力制药股份有限公司Chinese legal name: 海口奇力制药股份有限公司。
您可以探索含有相同成分的其他药品：利巴韦林-e1136c4c成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 奇力威林) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 利巴韦林Liba Weilin.
Manufacturers recorded for this product: 海口奇力制药股份有限公司Chinese legal name: 海口奇力制药股份有限公司.
Explore other medicines containing the same ingredient: 利巴韦林 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 奇力威林Recorded Chinese name: 奇力威林
- 剂型Dosage form: 注射剂Injection
- 规格Specification: 0.25g0.25 g
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 海口奇力制药股份有限公司Chinese legal name: 海口奇力制药股份有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20030523
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20030523
Manufacturer
Chinese legal name: 海口奇力制药股份有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
English translation unavailable. The original Chinese source label remains available below.
Specification
English translation unavailable. The original Chinese source label remains available below.
中文说明书原文Original Chinese source label
批准文号
国药准字H20030523
生产企业
海口奇力制药股份有限公司(国产)
适应症
本品为抗病毒药。主要用于病毒性上呼吸道感染。
用法用量
静脉滴注或肌内注射。 1.成人一日500mg-1000mg(一日5-10支)，分2次给药，疗程3-5天。 2.静脉滴注时，用葡萄糖或氯化钠注射液稀释成每1ml含1-2mg的溶液，缓慢滴入。
不良反应
1.本品毒性低。较常见的不良反应有贫血、乏力等。停药后即消失。
2.较少见的不良反应有疲倦、头痛、失眠等(多见于应用大剂量者)，以及食欲减退、恶心等。
禁忌
对本品有过敏者禁用，活动性结核不宜使用。
注意事项
1.对诊断干扰、口服或静脉给药引起血胆红激素增高者可高达25%。大剂量可引起血红蛋白量下降。
2.肝功能异常者慎用。
贮藏
密闭，在阴凉处保存.
规格
0.25g
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.